Astrana Health, Inc. (ASTH) fair value analysis
Nasdaq · Updated 2026-10-19
ASTH price how computed
Forward Fair Value verdict
UndervaluedASTH is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $36.81
- Sector
- Healthcare
- 12-month range
- $18.16–$49.81
- Market cap
- $1.83B
- From 52-week high
- -26.1%
- Shares outstanding
- 49.6M
- Rank in Healthcare by discount to fair value
- #99 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Astrana Health, Inc. is a healthcare company that provides managed care services and health insurance coverage to Medicare Advantage and Medicaid populations. The company operates across multiple states in the United States, delivering integrated healthcare services to its members.
ASTH currently ranks #99 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.83B
- P/E (trailing)
- 16x
- Revenue (TTM)
- $3.84B
- Net margin
- 1.1%
- EPS (TTM)
- $2.23
- Gross margin
- 10.7%
- Debt / equity
- 1.18
- Revenue growth (3-yr avg)
- 59.8%
- Shares outstanding
- 49.6M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 56 · neutral
- 50-day average
- $37.22
- 200-day average
- $33.34
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+29.0%)
2026-03 ▲ beat (+13.8%)
2025-12 ▲ beat (+308.0%)
2025-09 ▲ beat (+9.8%)
2025-06 ▼ miss (-47.2%)
2025-03 ▲ beat (+33.3%)
2024-12 ▲ beat (+71.8%)
2024-09 ▲ beat (+10.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 1 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $51.7
- Target vs last price
- +40.5%
What our data shows for ASTH
- Our model validated 17 trailing price-to-earnings windows for ASTH, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $18.16–$49.81.
- The 14-day relative strength index sits at a neutral 56.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ASTH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ASTH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ASTH's trend state has shifted from uptrend to mixed according to the 50/200-day moving average analysis tracked by TickrTrends this week. The stock remains classified as undervalued based on current valuation metrics within the healthcare sector. This transition to a mixed trend state suggests reduced directional momentum compared to the prior week's uptrend classification.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for ASTH showed a shift in the 50/200-day trend state this week, moving from mixed to uptrend. The stock maintains an undervalued valuation verdict in the Healthcare sector. This technical transition reflects a change in the stock's intermediate-term momentum compared to the previous week's assessment.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for ASTH showed movement in the Relative Strength Index this week, with the RSI zone shifting from oversold conditions to neutral territory. The stock maintains an undervalued valuation verdict according to current analysis.
- 2026-09-21 — ASTH's relative strength index moved into oversold territory this week, shifting from a neutral zone reading in the prior period. The stock remains classified as undervalued based on current valuation metrics within the healthcare sector. This combination of oversold momentum conditions and undervaluation positioning may be of interest to investors monitoring the stock's technical and fundamental status.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ASTH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ASTH is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ASTH's TickrTrends verdict?
ASTH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ASTH compare to other Healthcare stocks?
ASTH ranks #99 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ASTH overbought or oversold?
ASTH's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ASTH report earnings next?
ASTH's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does ASTH usually beat earnings estimates?
Over its last 8 reported quarters ASTH beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ASTH?
Of 11 analysts covering ASTH, 10 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $51.7 (+40.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ASTH vs ADMA · ASTH vs ALGN · ASTH vs ANIP · ASTH vs AZN · ASTH vs BSX